

# References

- Abildgaard N, Brixen K, Kristensen JE, Eriksen EF, Nielsen JL and Heickendorff L. (2003):** Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre-treatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy. *Br. J. Haematol*; 120(2), 235–242.
- Abraham RS, Clark RJ, Bryant SC, et al. (2002):** Correlation of serum immunoglobulin free light chain quantification with urinary Bence Jones protein in light chain myeloma. *Clin Chem*; 48:655-657.
- Akira Arimura, Min Li, and Vecihi Batuman (2006):** Potential protective action of pituitary adenylate cyclase-activating polypeptide (PACAP38) on in vitro and in vivo models of myeloma kidney injury. *American Society Of Hematology* ;107(2):661-667.
- Ambuj Kuma, Mohamed A., Kharfan-Dabaja, Axel Glasmacher and Benjamin Djulbegovic (2009):** Tandem Versus Single Autologous Hematopoietic Cell Transplantation for the Treatment of Multiple Myeloma. *Journal of the National Cancer* ;101(2):100-106.
- Anagnostopoulos A, Weber D, Rankin K, Delasalle K and Alexanian R. (2003):** Thalidomide and dexamethasone for resistant multiple myeloma. *Br J Haematol*; 121:768-771.
- Anderson G, Gries M, Kurihara N et al. (2006):** Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. *Blood*; 107(8), 3098–3105.
- Andrea Nozza , Licia Siracusano and Santoro Armando (2006):** Bortezomib-Dexamethasone Combination in a Patient with Refractory Multiple Myeloma and Impaired Renal Function. *Clin Ther*; 28:953-959.
- Angela Dispenzieri and Robert A. Kyle (2005):** Multiple Myeloma: Clinical features and indications for therapy. *Best practice & Research clinical Haematology* ;18(4):553-568.
- Angela Dispenzieri and Robert A. Kyle (2005):** Neurological aspects of multiple myeloma and related disorders. *Best Practice & Research Clinical Haematology*; 18(4): 673-688.
- Angtuaco EJ, Fassas AB, Walker R, Sethi R and Barlogie B. (2004):** Multiple myeloma: clinical review and diagnostic imaging. *Radiology*; 231(1), 11–23.
- Annettino AC, Farrugia AN, Kortesisidis A et al. (2005):** Elevated serum levels of stromal-derived factor-1  $\alpha$  are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. *Cancer Res*; 65(5), 1700–1709.
- Asher A. Chanan-Khan, Jonathan L. Kaufman, Jayesh Mehta, Paul G. Richardson, Kena C. Miller, Sagar Lonial, Nikhil C. Munshi, Robert Schlossman, Joseph Tariman, and Seema Singhal; (2007):** Activity and

## References

- safety of bortezomib in multiple myeloma patients with advance renal failure: a multicenter retrospective study. *The American Society of Hematology*; 109(6):2604-2607.
- Attal M, Harousseau JL, Facon T, et al. (2003):** InterGroupe Francophone du Myélome. Single versus double autologous stem-cell transplantation for multiple myeloma [published correction appears in *N Engl J Med*. 2004;350:2628]. *N Engl J Med*; 349:2495-2502
- Augustson BM, Begum G, Dunn JA, Barth NJ, Davies F, Morgan G, Behrens J, Smith A, Child JA and Drayson MT (2005):** Early mortality after diagnosis of multiple myeloma: Analysis of patients entered onto the United kingdom medical research council trials between 1980 and 2002—Medical Research Council Adult Leukaemia Working Party. *J Clin Oncol*; 23: 9219–9226.
- Badros A, Barlogie B, Siegel E et al. (2001):** Results of autologous stem cell transplant in multiple myeloma patients with renal failure. *Br J Haematol*; 114; 822–829.
- Badros A, Barlogie B, Siegel E, et al. (2002):** Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after non-meloablative conditioning. *J Clin Oncol*; 20:1295-1303.
- Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N, Badros A, Zangari M, Anaissie E, Epstein J, Shaughnessy J, Ayers D, Spoon D and Tricot G (2001):** Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients. *Blood*; 98: 492–494.
- Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD, McCoy J, Moore DF Jr, Dakhil SR, Lanier KS, Chapman RA, Cromer JN, Salmon SE, Durie B and Crowley JC (2006):** Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: Final results of phase III US Intergroup Trial S9321. *J Clin Oncol*; 24: 929–936.
- Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, Fassas A, Zangari M, Hollmig K, Pineda-Roman M, Lee C, Talamo G, Thertulien R, Kiwan E, Krishna S, Fox M and Crowley J (2006):** Thalidomide and hematopoietic-cell transplantation for multiple myeloma. *N Engl J Med*; 354: 1021–1030.
- Bastian Dehmel, Wolfgang Schneider, Ralph Kettritz and Friedrich C. Luft (2003):** Not so acute renal failure with crystals in the urine. *Nephrol Dial Transplant*; 18:209-211.
- Batuman V. (2007):** Proximal tubular injury in myeloma. *Contrib Nephrol*; 153: 87–104.
- Bellucci R and Ritz J. (2002):** Allogeneic stem cell transplantation for multiple myeloma. *Rev Clin Exp Hematol*; 6:205-224.

## References

- Bellucci R, Alyea EP, Weller E, et al. (2002):** Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma. *Blood*; 99:4610-4617.
- Berenson JR and Casciato DA. (2004):** Plasma cell dyscrasias and Waldenström's macroglobulinemia. In: Casciato DA, ed. *Manual of Clinical Oncology* 5th ed. Philadelphia: Lippincott Williams & Wilkins; 458-79.
- Bergsagel PL and Kuehl WM (2005):** Molecular pathogenesis and a consequent classification of multiple myeloma. *J Clin Oncol*; 23: 6333–6338.
- Blade J and Rosinol L (2007) :** Complications of Multiple Myeloma . *Hematol Oncol Clin North Am* ;(6):1231-46.
- Blade J, Rosinol L, Sureda A, Ribera JM, Diaz-Mediavilla J, Garcia-Larana J, Mateos MV, Palomera L, Fernandez-Calvo J, Marti JM, Giraldo P, Carbonell F, Callis M, Trujillo J, Gardella S, Moro MJ, Barez A, Soler A, Font L, Fontanillas M and San Miguel J (2005):** High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: Long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. *Blood*; 106: 3755–3759.
- Blade J. (2004):** Management of renal, hematologic, and infectious complications. In Malpas JS, Bergsagel DE, Kyle RA & Anderson KC (eds.) *Myeloma: Biology and Management*, 3rd edn. Philadelphia, PA: Saunders; pp. 251–267.
- Blade J, San Miguel JF, Fontanillas M et al. (2001):** Initial treatment of multiple myeloma: long-term results in 914 patients. *Hematol; J*; 2: 272–278.
- Boczkowski D, Nair SK, Nam JH, et al. (2000):** Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. *Cancer Res*; 60:1028-1034.
- Boyle WJ, Simonet WS and Lacey DL. (2003):** Osteoclast differentiation and activation. *Nature*; 423(6937), 337–342.
- Breitkreutz I, Raab MS, Vallet S et al. (2008):** Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. *Leukemia*; 22(10), 1925–1932.
- Breitkreutz I, Vallet S, Raab MS et al. (2006):** AZD6244 (ARRY-142886), a potent and selective MEK1/2 inhibitor blocks the ERK1/2 signaling pathway, inhibits osteoclast differentiation and activation in multiple myeloma: clinical implications. Presented at: 48th ASH Annual Meeting and Exposition. Orlando, FL, USA; 9–11.
- Carlson K, Hjorth M and Knudsen LM. (2005):** Nordic Myeloma Study Group: Toxicity in standard melphalan-prednisone therapy among myeloma patients with renal failure—a retrospective analysis and recommendations for dose adjustment. *Br J Haematol*; 128:631–635.

## References

- Carlson K. (2005):** Melphalan 200 mg/m<sup>2</sup> with blood stem cell support as first-line myeloma therapy: impact of glomerular filtration rate on engraftment, transplantation-related toxicity and survival. *Bone Marrow Transplant*; 35: 985–990.
- Casserly LF, Fadia A, Sanchorawala V et al. (2003):** High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease. *Kidney Int*; 63: 1051–1057.
- Cavo M, Zamagni E, Tosi P, et al. (2005):** Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. *Blood*; 106:35-39.
- Cesana C, Nosari AM, Klersy C et al. (2003):** Risk factors for the development of bacterial infections in multiple myeloma treated with two different vincristine–adriamycin–dexamethasone schedules. *Haematologica*; 88: 1022–1028.
- Chang H, Qi C, Yi Q-L et al. (2004):** P53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. *Blood*. First Edition Paper, prepublished online August 31, DOI 10.1182/blood; 04-1363.
- Chen N, Lau H, Kong L, Kumar G, Zeldis JB, Knight R et al. (2007):** Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. *J Clin Pharmacol* ; 47: 1466–1475.
- Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, Brown J, Drayson MT and Selby PJ (2003):** High dose therapy improves the outcome of patients with multiple myeloma: The MRC Myeloma VII randomized trial. *N Engl J Med*; 348: 1875–1883.
- Choufani EB, Sanchorawala U, Ernst T et al. (2001):** Acquired factor X deficiency in patients with amyloid light chain amyloidosis: incidence, bleeding manifestations and response to high-dose therapy. *Blood*; 97: 1885–1887.
- Coleman M, Leonard J, Lyons L, et al. (2002):** BLT-D (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenström's macroglobulinemia. *Leuk Lymphoma*; 43:1777-1782.
- Comenzo RL, Zhang Y, Martinez C, Osman K and Herrera GA (2001):** The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden. *Blood*; 98: 714–720.
- Crawley C, Lalancette M, Szydlo R, Gilleece M, Peggs K, Mackinnon S, Juliusson G, Ahlberg L, Nagler A, Shimoni A, Sureda A, Boiron JM, Einsele H, Chopra R, Carella A, Cavenagh J, Gratwohl A, Garban F, Zander A, Björkstrand B, Niederwieser D, Gahrton G and Apperley JF**

## References

- (2005): Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: An analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. *Blood*; 105:4532–4539.
- Cristina Gasparetto and Lee Moffitt (2004):** Cancer Center and Research Institute, Inc. Stem Cell Transplantation for Multiple Myeloma Cancer Center; 11(2)
- Dancey JE. (2002):** Agents targeting ras signaling pathway. *Curr Pharm Des*; 8:2259-2267.
- Delgado M and Ganea D. (2001):** Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit nuclear factor-kappa B dependent gene activation at multiple levels in the human monocytic cell line THP-1. *J Biol Chem*; 276:369-380.
- Dimitrios Christoulas, Evangelos Terpos and Meletios A. Dimopoulos (2009):** Pathogenesis and Management of Myeloma Bone Disease. Expert review of hematology; 2(4):385-398.
- Dimopoulos M, Terpos E, Comenzo RL et al. (2009):** International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma. *Leukemia* DOI; 10.1038/leu. 89 (Epub ahead of print).
- Dimopoulos MA, Anagnostopoulos A & Weber D. (2003):** Treatment of plasma cell dyscrasias with thalidomide and its derivatives. *J Clin Oncol*; 21: 4444–4454.
- Dimopoulos MA, Kastritis E, Rosinol L, Blade J and Ludwig H (2008):** Pathogenesis and treatment of renal failure in multiple myeloma. Spotlight review of leukemia; 22:1485-1493.
- Dimopoulos MA, Moulopoulos LA, Datskeris I et al. (2000):** Imaging of myeloma bone disease-implications for staging, prognosis and follow-up. *Acta Oncol*; 39(7), 823–827.
- Dimopoulos MA, Spencer A, Attal M, Prince M, Harousseau JL and Dmoszynska A (2005):** Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma: Results of a phase 3 study (MM-010). *ASH Annual Meeting*; Abstracts 106: 6.
- Dispenzieri A et al. (2003):** POEMS syndrome: definitions and long-term outcome. *Blood*; 101(7):2496–2506.
- Dovark C (2007) :** Common complaints, difficult diagnosis of MM. *J AM acad Nurse Pract* ; 18(5):190-194.
- Duncan L, Heathcote J, Djurdjev O and Levin A. (2001):** Screening for renal disease using serum creatinine: who are we missing? *Nephrol Dial Trans*;16: 1042–6.
- Durie BG, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro M et al. (2003):** Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. *Hematol J*; 4: 379–398.

## References

- Edmund J.Lamb, Helen J. Stowe, David E. Simpson, Anthony J. Coakley, David J. Newman and Maev Leahy (2004):** Diagnostic Accuracy of Cystatin C as a Marker of Kidney Disease in Patients with Multiple Myeloma. *Clinical Chemistry*; 50(10):1848-1851.
- Efstathios Kastritis, Athanasios Anagnostopoulos, Maria Roussou and Dimitra Gika (2007):** Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone containing regimens and the impact of novel agent. *Haematologica-the hematological journal* ;92:546-549.
- Eleutherakis-Papaiakovou V, Bamias A, Gika D, Simeonidis A, Pouli A, Anagnostopoulos A, et al. (2007):** Renal failure in multiple myeloma: Incidence, correlations, and prognostic significance. *Leuk Lymphoma*; 48: 337-41.
- Eriksson T, Hoglund P, Turesson I et al. (2003):** Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis. *J Pharm Pharmacol*; 55: 2702–2706.
- Eriksson T, Hoglund P, Turesson I, Waage A, Don BR, Vu J, Scheffler M, Estendorf JJ and Kahler RA(2004):** Schroeder TM. Wnt signaling in osteoblasts and bone diseases. *Gene*; 341, 19–39.
- Fassas AB, Muwalla F, Berryman T et al. (2002):** Myeloma of the central nervous system: association with high risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations. *Br J Haematol*; 117(1): 103–108.
- Fassas AB, Spencer T, Sawyer J, et al. (2002):** Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. *Br J Haematol*; 118:1041-1047.
- Fassas AB, Van Rhee F & Tricot G. (2003):** Predicting long-term survival in multiple myeloma patients following autotransplants. *Leuk Lymphoma*; 44: 749–758.
- Feng R, Ma H, Hassig CA et al. (2008):** KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling. *Mol. Cancer Ther*; 7(6), 1494–1505.
- Fonseca R, Bailey RJ, Ahmann GJ, et al. (2002):** Genomic abnormalities in monoclonal gammopathy of undetermined significance. *Blood*; 100: 1417-1424.
- Fonseca R, Barlogie B, Bataille R, et al. (2004):** Genetics and cytogenetics of multiple myeloma: a workshop report. *Cancer Res*; 64:1546-1558.
- Fonseca R, Blood EA, Oken MM et al. (2002):** Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. *Blood* ; 99: 3735–3741.
- Fonseca R, Harrington D, Oken MM et al. (2002):** Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study. *Cancer Res*; 62: 715–720.

## References

- Fourney DR, Schomer DF, Nader R, et al. (2003):** Percutaneous vertebroplasty and kyphoplasty for painful vertebral body fractures in cancer patients. *J Neurosurg*; 98(1, suppl):21-30.
- Francesco S. Vella, Barbara Simone, Gianluigi Giannelli, MariaTeresa Pesolo, Giuseppe Ingravallo, Antonia Gentile and Salvatore Antonaci; (2003):** Case of Multiple Myeloma Mimicking an Infectious Disease With Fever, Intrahepatic Cholestasis, Renal Failure, and Pulmonary Insufficiency. *American Journal of Hematology*; 72(1):38-42
- Frere P, Canivet JL, Gennigens C, et al (2000):** Hyperammonemia after high-dose chemotherapy and stem cell transplantation. *Bone Marrow Transplant*; 26:343-5.
- Fulcitini M, Tassone P, Hideshima T et al. (2007):** Anti-DKK1 mAb (BHQ880) as a potential therapeutic for multiple myeloma. Presented at: 49th ASH Annual Meeting and Exposition. Atlanta, GA, USA; 8–11.
- Furer V, Heyd J. (2007):** Hyperammonemic encephalopathy in multiple myeloma. *IMAJ*; 9:557-9.
- Gahrton G, Svensson H, Cavo M, et al. (2001):** Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centres. *Br J Haematol*; 113:209-216.
- Ganea D and Delgado M. (2001):** Neuropeptides as modulators of macrophage functions. Regulation of cytokine production and antigen presentation by VIP and PACAP. *Arch Immunol Ther Exp (Warsz)*; 49:101-110.
- García-Sanz R, González-Fraile MI, Mateo G et al. (2004):** Proliferative activity of plasma cells is the most relevant prognostic factor in elderly multiple myeloma patients. *Int J Cancer* ; 112: 884–889.
- Gemmel C, Cremer FW, Weis M, et al. (2002):** Anti-CD20 antibody as consolidation therapy in a patient with primary plasma cell leukemia after high-dose therapy and autologous stem cell transplantation. *Ann Hematol*; 81:119-123.
- Gertz MA, Lacy MQ, Dispenzieri A et al. (2002):** A multicenter phase II trial of 40-iodo-40deoxydoxorubicin in primary amyloidosis (AL). *Amyloid*; 9: 24–30
- Ghobrial IM, Dispenzieri A, Bundy KL, et al. (2003):** Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma. *Bone Marrow Transplant*; 32:587-592.
- Ghobrial IM, Dispenzieri A, Bundy KL, et al. (2003):** Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma. *Bone Marrow Transplant*; 32:587-592.
- Gordon S, Helfrich MH, Sati HI et al. (2002):** Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma. *Br. J. Haematol*; 119(2), 475–483.

## References

- Greipp PR et al. (2003)** A new international staging system (ISS) for multiple myeloma (MM) from the international myeloma working group. *Blood*; 102(11): 190a–191a
- Greipp PR, San Miguel J, Durie BGM, Crowley JJ, Barlogie B, Blade J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I and Westin J (2005)**: International staging system for multiple myeloma. *J Clin Oncol*; 23: 3412–3420.
- Gupta D, Treon SP, Shima Y, et al. (2001)**: Adherence of multiple myeloma cells to bone marrowstromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. *Leukemia*; 15: 1950- 1961.
- Gutierrez NC, Garcia JL, Herná'ndez JM et al. (2004)**: Prognostic and biological significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma. *Blood*. First Edition Paper, prepublished online July 6, DOI 10.1182/blood; 04-1319.
- Harris E, Behrens J, Samson D, Rahemtulla A, Russell NH and Byrne JL. (2003)**: Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia. *Br J Haematol*; 122: 160–161.
- Hartmut Goldschmidt, Heinrich Lannert, Jurgen Bommer and Anthony D. Ho (2000)**: Multiple Myeloma and Renal Failure. *Nephrol Dial Transplant*; 15(3):301-304.
- Hartmut Goldschmidt, Heinrich Lannert, Jurgen Bommer and Anthony D. Ho (2001)**: Renal Failure in Multiple Myeloma. *Saudi Journal of Kidney Disease and Transplantation* ;12(2):145-150.
- Heinz Ludwig, Johannes Drach, Helmut Graf, Alois Lang and Johannes Gobertus Meran (2007)**: Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma. *Haematologica-the hematological Journal*; 92:1411-1414.
- Heiser A, Dahm P, Yancey DR, et al. (2000)**: Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate specific CTL responses in vitro. *J Immunol*; 164: 5508-5514.
- Henrich DM, Hoffmann M, Uppenkamp M and Bergner R. (2006)**: Ibandronate in the treatment of hypercalcemia or nephrocalcinosis in patients with multiple myeloma and acute renal failure. *Acta Haematol*; 116:165-172.
- Herrera GA, Joseph L, Gu X, Hough A and Barlogie B (2004)**: Renal pathologic spectrum in an autopsy series of patients with plasma cell dyscrasia. *Arch Pathol Lab Med*; 128:875–879.
- Herrera GA. (2000)**: Renal manifestations of plasma cell dyscrasias: an appraisal from the patients' bedside to the research laboratory. *Ann Diagn Pathol*; 4:174–200.
- Hideshima T, Bergsagel PL, KuehlWM & Anderson KC (2004)**: Advances in biology of multiple myeloma: clinical applications. *Blood*; 104: 607–618.

## References

- Hideshima T, Chauhan D, Shima Y, et al. (2000):** Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. *Blood*; 96: 2943-2950.
- Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ and Riggs BL. (2000):** The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. *J. Bone Miner. Res*; 15(1), 2–12.
- Holahan JR. (2004):** Hyperammonemia: elevated ammonia levels in multiple myeloma. *Am J Med*; 116:210-1.
- Howe HL et al. (2001):** Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. *J Natl Cancer Inst*; 93(11): 824–842.
- Huff CA, Fuchs EJ, Noga SJ, et al. (2003):** Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells. *Biol Blood Marrow Transplant*; 9:312-319.
- Hutchison CA, Cockwell P, Reid S, Chandler K, Mead GP, Harrison J et al. (2007):** Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. *J Am Soc Nephrol* ; 18: 886–895.
- Hutchison CA, Cook M, Basu S, Cockwell P, Basnayake K and Bradwell A. (2007):** Combined chemotherapy and high cut-off hemodialysis improve outcomes in multiple myeloma patients with severe renal failure. *Blood* 110. hybridization. *Blood*; 95: 1925–1930.
- Idoya Ancín, Josep Sarrá, Juan Peris, Vicente Romagosa, Alicia Domingo – Claros and Alberto Grañena (2000):** Demonstration of Epstein-Barr virus in a case of multiple myeloma after renal transplantation. *Haematologica-scientific correspondence*; 85(7):773-774.
- Irfan yavasolgu , Zahil bolama, Mustafa unubol and Gurhan kadihoylu; (2008):** Hemoptysis as a presenting sign of multiple myeloma. *Respiratory medicine*;102:1672-1673.
- Jaffe ES, Harris NL, Stein H et al. (2001)** Pathology and genetics of tumours of the hematolymphoid tissues. Lyon: IARC Press; 264–269.
- Jagannath S, Barlogie B, Berenson JR, et al, (2005):** for the SUMMIT/CREST Investigators. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impaired renal function. *Cancer*; 103:1195-1200.
- Jagannath S, Barlogie B, Berenson J, et al. (2003):** Limited experience from 2 phase 2 trials suggests bortezomib can be given safely in multiple myeloma (MM) patients (pts) with severe renal impairment with comparable responses and toxicities. *Blood*; 102:Abstract 828.
- Jaime Lora-Tamayo, Xavier Palom, José Sarrá, Oriol Gasch, Virginia Isern, Alberto Fernández de Sevilla and Ramón Pujol (2008):** Multiple Myeloma and Hyperammonemic Encephalopathy: Review of 27 Cases. *Clinical Lymphoma & Myeloma*; 8(6):363-369.

## References

- Jakob C, Sterz J and Kleeberg L. (2005):** Serum total-RANKL is elevated in patients with multiple myeloma, increases with ISS stage and decreases under induction therapy. *Blood*; 11.
- James Hanje, Jennifer L. Shamp, Pharm.D, Fred B. Thomas and Greg M. Meis (2005):** Thalidomide Induced Sever Hepatotoxicity. *Pharmacotherapy Publications*; 26(7):1018-1022.
- Jeffrey G and Penfield (2006):** Multiple Myeloma in End-Stage Renal Disease. *Seminars in Dialysis* ;19(4):329-334.
- Jesus F. San Miguel and Ramon Garcia-San (2005):** Prognostic features of multiple myeloma. *Best Practice & Research Clinical. Haematology* ;18(4):569-583.
- Joan blade and Laura Rosinol (2005):** Renal, Heamatological and Infectious Complications of Multiple Myeloma. *Best practice & Research clinical Heamatology*; 18(4):635-652.
- Katzmann JA, Clark RJ, Abraham RS, et al. (2002):** Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. *Clin Chem*; 48:1437-1444.
- Kay NE, Leong TL, Bone N et al. (2001):** Blood levels of immune cells predict survival in myeloma patients: results of an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed multiple myeloma patients. *Blood* ; 98: 23–28.
- Kaysen GA (2003):** Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis. *J Pharm Pharmacol*; 55:1701–1706.
- Kazuo Dan (2003):** Thalidomide as a Targeted Therapy for Multiple Myeloma. *Internal Medicine*; 42(7):550-551.
- Keeling J and Herrera GA. (2007):** The mesangium as a target for glomerulopathic light and heavy chains: pathogenic considerations in light and heavy chain-mediated glomerular damage. *Contrib Nephrol*; 153: 116–134.
- Keeling J, Teng J and Herrera GA (2004):** AL-amyloidosis and lightchain deposition disease light chains induce divergent phenotypic transformations of human mesangial cells. *Lab Invest*; 84: 1322–1338.
- Kelleher P & Chapel H.(2002):** Infections: principles of prevention and therapy. In Metha J & Singhal S (eds.) *Myeloma*. London: Martin Dunitz Ltd; pp. 223–239.
- Keller LS, Faull RJ, Smith P, Swift J, Bannister KM, Otto S, et al. (2005):** Crystalloid deposits in the kidney. *Nephrology (Carlton)*; 10:81-3.
- Kim SB, Baskar S and Kwak LW. (2003):** In vitro priming of myeloma antigen-specific allogeneic donor T cells with idiotype pulsed dendritic cells. *Leuk Lymphoma*; 44:1201-1208.

## References

- Knudsen LM, Hjorth M and Hippe E. (2000):** Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. *Eur J Haematol*; 65:175-81.
- Knudsen LM, Nielsen B, Gimsing P and Geisler C. (2005):** Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure. *Eur J Haematol*; 75:27-33.
- Kostenuik P, Nguyen H, McCabe J et al. (2009):** Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases bone density in knock-in mice that express chimeric (murine/human) RANKL. *J. Bone Miner. Res*; 24(2), 182–195.
- Kraj M, Owczarska K, Sokolowska U, Centkowski P, Poglód R and Kruk B. (2005):** Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients. *Arch Immunol Ther Exp*; 53:454-64.
- Kroeger N, Schwerdtfeger R, Kiehl M et al. (2002):** Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. *Blood*; 100: 755–760.
- Kroger N, Schwerdtfeger R, Kiehl M, et al. (2002):** Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. *Blood*; 100: 755-760.
- Kropff MH, Lang N, Bisping G, et al. (2003):** Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. *Br J Haematol*; 122:607-616.
- Kuehl WM and Bergsagel PL. (2002):** Multiple myeloma: evolving genetic events and host interactions. *Nat Rev Cancer*; 2:175-187.
- Kumar A, Loughran T, Alsina M, Durie BG and Djulbegovic B. (2003):** Management of multiple myeloma: a systematic review and critical appraisal of published studies. *Lancet Oncol*; 4:293-304.
- Kumar S, Kimlinger TK, Lust JA, et al. (2003):** Expression of CD52 on plasma cells in plasma cell proliferative disorders. *Blood*; 102: 1075-1077.
- Kumar S, Lacy MQ, Dispenzieri A, Rajkumar SV, FonsecaR, Geyer S, Allmer C, Witzig TE, Lust JA, Greipp PR, KyleRA, Litzow MR and Gertz MA (2004):** Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma. *Bone Marrow Transplant*; 34: 485–490.
- Kumar S, Witzig TE and Rajkumar SV. (2004):** Thalidomide: current role in the treatment of non-plasma cell malignancies [published correction appears in *J Clin Oncol*; 22:2973]. *J Clin Oncol*; 22:2477-2488.
- Kyle RA (2001):** Henry Bence Jones—physician, chemist, scientist and biographer: a man for all seasons. *Br J Haematol*; 115:13–18.
- Kyle RA and Rajkumar SV (2004):** Multiple myeloma. *N Engl J Med*; 351: 1860–1873.

## References

- Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. (2003):** Review of 1027 patients with newly diagnosed multiple myeloma. *Mayo Clin Proc* ; 78:21-33.
- Kyle RA, Therneau TM, Rajkumar SV et al. (2002):** A long-term study of prognosis in monoclonal gammopathy of undetermined significance. *N Engl J Med*; 346: 564–569.
- Kyle RA, Yee GC, Somerfield MR et al. (2007):** American society of clinical oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. *J. Clin. Oncol*; 25(17), 2464–2472.
- Lahuerta JJ, Martinez-Lopez J, Serna JD et al. (2000):** Remission status defined by immunofixation vs electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. *Br J Haematol*; 109: 438–446.
- Lee JW, Chung HY, Ehrlich LA et al. (2004):** IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. *Blood*; 103(6), 2308–2315.
- Lelievre V, Pineau N and Waschek JA. (2003):** The biological significance of PACAP and PACAP receptors in human tumors: from cell lines to cancers. In: Vaudry H, Arimura A, eds. *Pituitary adenylate cyclase-activating polypeptide*. Norwell, MA: Kluwer Academic Publishers; 361-399.
- Levey AS, Greene T and Kusek JW. (2000):** A simplified equation to predict glomerular filtration rate from serum creatinine. *J Am Soc Nephrol*; 11:A0828.
- Lin J, Markowitz GS, Valeri AM, Kambham N, Sherman WH, Appel GB and D'Agati VD (2001):** Renal monoclonal immunoglobulin deposition disease: The disease spectrum. *J Am Soc Nephrol*; 12: 1482–1492.
- Ludwig H and Fritz E (2002):** Supportive therapy. In: *Myeloma*, edited by Mehta J, Singhal S, London, Martin Dunitz; pp 397–412.
- Ludwig H, Rai K, Blade J et al. (2001):** Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoetin treatment recommendations. *Hematol J*; 3: 121–130.
- Lundin J, Kimby E, Bjorkholm M, et al. (2002):** Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). *Blood*; 100:768-773.
- Ma CX et al. (2004):** Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma. *Blood*; 104(1): 40–42.
- Mai HL, Sheikh-Hamad D, Herrera GA, Gu X and Truong LD (2003):** Immunoglobulin heavy chain can be amyloidogenic: Morphologic characterization including immunoelectron microscopy. *Am J Surg Pathol*; 27: 541–545.
- Major P, Lortholary A, Hon J, et al. (2001):** Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled

## References

- analysis of two randomized, controlled clinical trials. *J Clin Oncol*; 19:558- 567.
- Maloney DG, Molina AJ, Sahebi F et al. (2003):** Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. *Blood*; 102: 3447–3454.
- Manganelli P, Fietta P, Carotti M, Pesci A and Salaffi F. (2006):** Respiratory system involvement in systemic vasculitides. *Clin Exp Rheumatol*; 24: S48e59.
- Marion Haubitz and Dietrich Peest (2006):** Myeloma \_New approaches to combind nephrological heamatological management. *Nephrol Dial Transplant* ; 21 (3): 582-590.
- Marion, D and Myeloma Trialists’ (2001):** Collaborative Group. Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. *Br J Haematol*; 113: 1020–1034
- Markowitz GS, Fine PL, Stack JI, Kunis CL, Radhakrishnan J, Palecki W, Park J, Nasr SH, Hoh S, Siegel DS and D’Agati VD (2003)::** Toxic acute tubular necrosis following treatment with zoledronate (Zometa). *Kidney Int*; 64:281–289.
- McCloskey EV, Dunn JA, Kanis JA, MacLennan IC and Drayson MT. (2001):** Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. *Br. J. Haematol*; 113(4), 1035–1043.
- Menssen HD, Sakalova A, Fontana A et al. (2002):** Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. *J. Clin. Oncol*; 20(9), 2353–2359.
- Messiaen T, Deret S, Mougenot B et al. (2000):** Adult Fanconi syndrome secondary to light chain gammopathy. Clinicopathologic heterogeneity and unusual features in 11 patients. *Medicine*; 79: 135–154.
- Mitsiades CS, Mitsiades N, Munshi NC and Anderson KC (2004):** Focus on multiple myeloma. *Cancer Cell*; 6: 439–444.
- Mitsiades CS, Mitsiades NS, Munshi NC, Richardson PG and Anderson KC. (2006):** The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. *Eur. J. Cancer*; 42(11), 1564–1573.
- Moestrup SK and Verroust PJ. (2001):** Megalin- and cubulin-mediated endocytosis of protein-bound vitamins, lipids, and hormones in polarized epithelia. *Annu Rev Nutr*; 21:407–428.
- Montagut C, Bosch F, Villela L, Rosinol L and Blade J. (2004):** Aminoglycoside- associated severe renal failure in patients with multiple myeloma treated with thalidomide. *Leuk Lymphoma*; 45: 1711–1712.
- Moreau P, Facon T, Attal M, et al. (2002):** Intergroupe Francophone du Myélome. Comparison of 200 mg/m<sup>2</sup> melphalan and 8 Gy total body

## References

- irradiation plus 140 mg/m<sup>2</sup> melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial. *Blood*; 99:731-735.
- Moreau P, Facon T, Leleu X et al. (2002):** Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. *Blood*; 100: 1579–1583.
- Morie A Gertz (2005):** Managing Myeloma Kidney. *Annals of internal medicine*; 143:835-837.
- Mukherjee S, Raje N, Schoonmaker JA et al. (2008):** Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. *J. Clin. Invest*; 118(2), 491–504.
- Mulkerin D, Remick S, Takimoto C, Ivy P, Karol M and Eton O. (2007):** Safety, Tolerability, and Pharmacology of Bortezomib in Cancer Patients with Renal Failure Requiring Dialysis: Results from a Prospective Phase 1 Study. *Blood* ; 110 (Abstract #3477).
- Munshi NC. (2001):** Arsenic trioxide: an emerging therapy for multiple myeloma. *Oncologist*; 6(suppl 2):17-21.
- Musto P, Petrucci MT, Brinchen S et al. (2008):** A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. *Cancer*; 113(7), 1588–1595.
- Nelson Leung (2006):** Plasma Exchange in Multiple Myeloma *Annals of Internal Medicine*; 144(6):455.
- Niesvizky R, Jayabalan DS, Christos PJ, Furst JR, Naib T, Ely S et al. (2008):** BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide] / dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. *Blood* ; 111: 1101–1109.
- Niesvizky R, Naib T, Christos PJ, Jayabalan D, Furst JR, Jalbrzikowski J et al. (2007):** Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naive patients undergoing front-line lenalidomide and dexamethasone therapy. *Br J Haematol*; 138: 640–643.
- Novak L, Cook WJ, Herrera GA and Sanders PW (2004):** AL-amyloidosis is underdiagnosed in renal biopsies. *Nephrol Dial Transplant*; 19: 3050–3053.
- Nperi, S. Kussick, R. Bakthavatsalam, L. Mitsumori and M. Dighea; (2006):** Postrenal Transplant Non-EBV Multiple Myeloma of Donor Origin. *American Journal of Transplantation*; 6:419–422.
- O’Riordan SE, Webb MC, Stowe HJ, Simpson DE, Kandarpa M, Coakley AJ, et al. (2003):** Cystatin C improves the detection of mild renal dysfunction in older patients. *Ann Clin Biochem*; 40:648–55.

## References

- Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. (2002):** Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. *J Clin Oncol*; 20: 4420-4427.
- Oshima K, Kanda Y, Nannya Y, Kaneko M, Hamaki T, Suguro M, Yamamoto R, Chizuka A, Matsuyama T, Takezako N, Miwa A, Togawa A, Niino H, Nasu M, Saito K and Morito T.(2001):** Clinical and pathologic findings in 52 consecutively autopsied cases with multiple myeloma. *Am J Hematol*; 67:1-5.
- Palumbo A, Bertola A, Musto P, et al. (2004):** A prospective randomized trial of oral melphalan, prednisone, thalidomide (MPT) vs oral melphalan, prednisone (MP): an interim analysis. *Blood*; 104(11, pt 1):63a.
- Palumbo A, Brinchen S, Caravita T, Merla E, Capparella V, Callea V, Cangialosi C, Grasso M, Rossini F, Galli M, Catalano L, Zamagni E, Petrucci MT, De Stefano V, Ceccarelli M, Ambrosini MT, Avonto I, Falco P, Ciccone G, Liberati AM, Musto P and Boccadoro M (2006):** Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomised controlled trial. *Lancet*; 367: 825-831.
- Paueksakon P, Revelo MP, Horn RG, Shappell S and Fogo AB (2003):** Monoclonal gammopathy: Significance and possible causality in renal disease. *Am J Kidney Dis*; 42: 87-95.
- Pearse RN, Sordillo EM, Yaccoby S et al. (2001):** Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. *Proc. Natl Acad. Sci. USA*; 98(20), 11581-11586.
- Pepys MB, Herbert J, Hutchinson WI et al. (2002):** Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. *Nature*; 417: 254-259
- Perez-Simon JA, Martino R, Alegre A et al. (2003):** Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation. *Br J Haematol*; 121(1): 104-108.
- Pineda-Roman M and Tricot G. (2007):** High dose therapy in patients with plasma cell dyscrasias and renal dysfunction. *Contrib Nephrol*; 153:182-94.
- Powles R, Sirohi B, Kulkarni S, Treleaven J, Rudin C, Sankpal S, Goyal S, Horton C, Millar B, Saso R, Singhal S and Mehta J (2002):** Collection of peripheral blood stem cells in newly diagnosed myeloma patients without any prior cytoreductive therapy: The first step towards an 'operational cure'? *Bone Marrow Transplant*; 30: 479-484.
- Pozzi C, Da' mico M, Fogazzi GB, Curionie S, Ferrario F, Pasquali S et al. (2003):** Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors. *Am J Kidney Dis*; 42: 1154-1163

## References

- Rajkumar SV and Kyle RA (2005):** Multiple myeloma: Diagnosis and treatment. *Mayo Clin Proc*; 80: 1371–1382.
- Rajkumar SV and Kyle RA. (2005):** Conventional therapy and approach to management. *Best Pract Res Clin Haematol*; 18:585-601.
- Rajkumar SV et al (2001):** Methods for estimation of bone marrow plasma cell involvement in myeloma: predictive value for response and survival in patients undergoing autologous stem cell transplantation. *Am J Hematol*; 68(4): 269–275
- Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR (2006):** Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. *J Clin Oncol*; 24: 431–436.
- Rajkumar SV, Gertz MA, Kyle RA and Greipp PR. (2002):** Mayo Clinic Myeloma, Amyloid, and Dysproteinemia Group. Current therapy for multiple myeloma. *Mayo Clin Proc*; 77:813-822.
- Rajkumar SV, Gertz MA, Lacy MQ, et al. (2003):** Thalidomide as initial therapy for early-stage myeloma. *Leukemia*; 17:775-779.
- Rajkumar SV, Hayman S, Gertz MA, et al. (2002):** Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. *J Clin Oncol*; 20:4319-4323.
- Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A, Geyer SM, Kabat B, Zeldenrust SR, Kumar S, Greipp PR, Fonseca R, Lust JA, Russell SJ, Kyle RA, Witzig TE and Gertz MA (2005):** Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. *Blood*; 106: 4050–4053.
- Rajkumar SV, Hayman SR, Lacy MQ, et al. (2004):** Combination therapy with CC-5013 (lenalidomide; Revlimid™) plus dexamethasone (Rev/Dex) for newly diagnosed myeloma (MM) [abstract]. *Blood*; 2004;104(11, pt 1):98a.
- Rajkumar SV, Mesa RA, Fonseca R, et al. (2002):** Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. *Clin Cancer Res*; 2002;8:2210- 2216.
- Rajkumar SV. (2005):** Multiple myeloma: the death of VAD as initial therapy. *Blood*; 106:2-3.
- Rebecca Wingard (2004):** Increased risk of anemia in dialysis patients with comorbid diseases. *Nephrology Nursing Journal*; 31(2):211-214.
- Richardson PG, Barlogie B, Berenson J, et al. (2003):** A phase 2 study of bortezomib in relapsed, refractory myeloma. *N Engl J Med*; 348:2609-2617.
- Richardson PG, Briemberg H, Jagannath S, et al (2004):** for the SUMMIT and CREST study group. Characterization and reversibility of peripheral

## References

- neuropathy in patients with advanced multiple myeloma treated with bortezomib (VELCADE). *Hematol J*; 5:\$129.
- Richardson PG, Chanan-Khan A, Schlossman RL, et al. (2004):** Phase II trial of single agent bortezomib (VELCADE®) in patients with previously untreated multiple myeloma (MM) [abstract]. *Blood*; 104(11, pt 1):100a. Abstract 336.
- Richardson PG, Schlossman RL, Weller E et al. (2002):** Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. *Blood*; 100: 3063–3067.
- Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. (2005):** Assessment of proteasome inhibition for extending remissions (APEX) investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. *N Engl J Med*; 352: 2487-98.
- Rizzo JD, Lichtin AE, Woolf SH et al. (2002):** Use of epoetin in patients with cancer: evidence-based clinicalpractice guidelines of the American Society of Clinical Oncology and The American Society oHematology. *J Clin Oncol*; 20: 40–83.
- Rodrigo Santucci, Paul A. Mackley, Saïd Sebti and Melissa Alsina (2003):** Farnesyltransferase Inhibitors and Their Role in the Treatment of multiple Myeloma. *Cancer Center and Research Institute*; 10(5):1-8.
- Ronco P, Plaisier E, Mougnot B and Aucouturier P. (2006):** Immunoglobulin light (heavy)-chain deposition disease: from molecular medicine to pathophysiology-driven therapy. *Clin J Am Soc Nephrol*; 1: 1342–1350.
- Roodman GD (2002):** Role of the bone marrow microenvironment in multiple myeloma. *J Bone Miner Res*; 17:1921-1925.
- Rosen LS, Gordon D, Kaminski M, et al. (2001):** Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. *Cancer J*; 7:377-387.
- Roucher PI, De Hendrik R, Perry MJ et al. (2003):** Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. *J. Bone Miner. Res*; 18(30), 482–492.
- Roxanne Nelson (2009):** Novel hemodialysis procedure helps restore renal function in multiple myeloma patients. *Clin J Am Soc Nephrol*; 4:745–754.
- Saif MW, Allegra CJ and Greenberg B. (2001):** Bleeding diathesis in multiple myeloma. *J Hematother Stem Cell Res*; 10(5): 657–660.
- Saito O, Kurosu M, Ando Y, Kusano E and Asano Y. (2000):** High PTHrP level induced hypercalcemia and acute renal failure in a multiple myeloma patient. *Nippon Jinzo Gakkai Shi*; 42: 41–46.

## References

- San Miguel JF and Garcí'a-Sanz R. (2004):** Multiple myeloma: differential diagnosis and prognosis. In Gahrton G, Durie DGM & Samson Dm (eds.) Multiple Myeloma and Related Disorders. Oxford University Press, New York; 179–199.
- San Miguel JF, Almeida J and Orfao A (2002):** Laboratory investigations. In: Myeloma, edited by Mehta J, Singhal S, London, Martin Dunitz, 243–268.
- San Miguel JF, Lahuerta JJ, Garcia-Sanz R et al. (2000):** Are myeloma patients with renal failure candidates for autologous stem cell transplantation? Hematol J; 1: 28–36
- Sanchorawala V, Wright DG, Seldin DC et al. (2001):** An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL-amyloidosis. Bone marrow Transplant; 28: 637–642.
- San-Miguel JF, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA et al. (2008):** Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia ; 22: 842–849.
- Santostefano M, Zanchelli F, Zaccaria A, Poletti G, Fusaroli M. (2005):** The ultrastructural basis of renal pathology in monoclonal gammopathies. J Nephrol; 18: 659–675.
- Schaar CG, Kluin-Nelemans JC, le Cessie S et al. (2004):** Early response to therapy and survival in multiple myeloma. Br J Haematol; 125: 162–166.
- Seema Singhal and Jayesh Mehta (2006):** Multiple Myeloma, Moving Points in Nephrology. Clin J Am Soc Nephrol ; 1(6):1322-1330.
- Seema, J Mitsiades CS, Mitsiades N, Munshi NC and Anderson KC (2004):** Focus on multiple myeloma. Cancer Cell; 6: 439–444.
- Seidel C, Sundan A, Hjorth M et al. (2000):** Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood; 95: 388–392.
- Seidl S, Kaufmann H and Drach J. (2003):** New insights into the pathophysiology of multiple myeloma. Lancet Oncol; 4: 557–564.
- Sengul S, Zwizinski C and Batuman V. (2003):** Role of MAPK pathways in light chain-induced cytokine production in human proximal tubule cells. Am J Physiol Renal Physiol; 284: F1245–F1254.
- Shaughnessy J. (2003):** Scientific and clinical applications of DNA microarrays—multiple myeloma as a disease model. PHD Mayo Clin Proc; 78: 1098–1109.
- Shaughnessy Jr J, Barlogie B, McCoy JPJ et al. (2001):** Early relapse after total Therapy II for multiple myeloma is significantly associated with cytogenetic abnormalities of chromosome 13 (CA13) but not interphase FISH-del 13 or plasma cell labeling index (PCLI). Blood; 98(supplement): 734a.
- Shilpi pradhan and Philip custer; (2006):** Multiple Myeloma presenting in the lacrimal sac. Am J Ophthalmol; 141:563-564.

## References

- Singhal S and Mehta J (2006):** Treatment of relapsed and refractory multiple myeloma. *Curr Treat Options Oncol* 4: 229–237, 2003 *1330 Clinical Journal of the American Society of Nephrology Clin J Am Soc Nephrol*; 1: 1322–1330.
- Singhal S, Powles R, Sirohi B, Treleaven J, Kulkarni S and Mehta J (2002):** Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma. *Bone Marrow Transplant*; 30: 673–679.
- Smith KD, Wrenshall LE, Nicosia RF, Pichler R, Marsh CL, Alpers CE, Polissar N and Davis CL (2003):** Delayed graft function and cast nephropathy associated with tacrolimus plus rapamycin use. *J Am Soc Nephrol*; 14:1037–1045.
- Stephen M. Korbet and Melvin M. Schwartz (2006):** Multiple Myeloma Disease Of The Month. *J Am Soc Nephrol* ;17(9):2533-45.
- Streetly M, Jones RW, Knight R, et al. (2003):** An update of the use and outcomes of the new immunomodulatory agent CC-4047 (Actimid) in patients with relapsed/refractory myeloma [abstract]. *Blood*; 102(11, pt 1):236a.
- Sun X, Peterson LC, Gong Y, Traynor AE and Nelson BP. (2004):** Posttransplant plasma cell myeloma and polymorphic lymphoproliferative disorder with monoclonal serum protein occurring in solid organ transplant recipients. *Mod Pathol*; 17: 389–394.
- Sze DM, Giesajtis G, Brown RD et al. (2001):** Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8(C)CD57(C)CD28(K) compartment. *Blood* ; 98: 2817–2827.
- Takeuchi K, Abe M, Oda A et al. (2006):** SB431542, a TGF- $\beta$  receptor kinase inhibitor, restores bone formation which ameliorates myeloma-induced microenvironment. Presented at: 48th ASH Annual Meeting and Exposition. Orlando, FL, USA; 9–11.
- Talamo G, Cavallo F, Zangari M, et al. (2007):** Hyperammonemia and encephalopathy in patients with multiple myeloma. *Am J Hematol*; 82:414-5.
- Teng J, Russell WJ, Gu X, Cardelli J, Jones ML and Herrera GA (2004):** Different types of glomerulopathic light chains interact with mesangial cells using a common receptor but exhibit different intracellular trafficking patterns. *Lab Invest*; 84: 440–451.
- Terpos E, Heath DJ, Rahemtulla A et al. (2006):** Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor- $\kappa$ B ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. *Br. J. Haematol*; 135(5), 688–692.
- Terpos E, Kastritis E, Roussou M et al. (2008):** The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with

## References

- improvement of abnormal bone metabolism and angiogenesis. *Leukemia*; 22(12), 2247–2256.
- Terpos E, Katodritou E, Tsiftsakis E, Kastritis E, Pouli A, Christoulas D et al. (2007):** Cystatin-C is a sensitive marker of renal impairment with an independent predictive value for survival in multiple myeloma; reduction post bortezomib monotherapy. *Blood*; 110 (Abstract #1484).
- Terpos E, Szydlo R, Apperley JF et al. (2003):** Soluble receptor activator of nuclear factor  $\kappa$ B ligand–osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. *Blood*; 102(3), 1064–1069.
- Thomas C. Pearson (2000):** Kidney Donation and Transplantation for Primary Amyloidosis. *Med. Transplantation*; 1(2)1.
- Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B and Shaughnessy JD Jr (2003):** The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. *N Engl J Med*; 349: 2483–2494.
- Tosi P, Zamagni E, Cellini C et al. (2006):** First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. *Eur. J. Haematol*; 76(5), 399–404.
- Treon SP, Shima Y, Grossbard ML, et al. (2000):** Treatment of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens. *Ann Oncol*; 11:107-111.
- Tucci M, Grinello D, Cafforio P et al. (2002):** Anemia in multiple myeloma: role of deregulated plasma cell apoptosis. *Leuk Lymph*; 43: 1527–1530.
- Uchida T, Kinoshita T, Ohno T et al. (2001):** Hypermethylation of p16INK4A gene promoter during the progression of plasma cell dyscrasia. *Leukemia*; 15: 157–165.
- Vanderkerken K, De Leenheer E, Shipman C et al. (2003):** Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. *Cancer Res*; 63(2), 287–289.
- Veselina Goranova-Marinova, Stefan Goranov, Pavel Pavlov and Todorka Tzvetkova (2007):** Serum levels of OPG, RANKL and RANKL/OPG ratios in newly-diagnosed patients with multiple myeloma. *Haematologica-the hematological Journal*; 92(7):1000-1001.
- Vincent S. Rajkumar and Robert A. Kyle (2005):** Multiple Myeloma: Diagnosis and Treatment. *Haematological Malignancies By Mayo clinic Pro*; 80 (10): 1371-1382.
- Vladimir Gavrilov, Tikva Yermiahu, and Rafael Gorodischer (2003):** Urinary Excretion of Retinol in Patients With Multiple Myeloma: A Preliminary Study. *American Journal of Hematology*; 74(3):202–204.
- Walker R, Barlogie B, Haessler J et al. (2007):** Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. *J. Clin. Oncol*; 25(9), 1121–1128.
- Wardle EN. (2002):** Antagonism of nuclear factor kappa B. *Nephron*; 90: 239.

## References

- Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. (2003):** Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. *J Clin Oncol*; 21:16-19.
- William F. Clark, Keith Stewart, Gail A. Rock, Marion Sternbach, David M. Sutton and Brendan J. (2005):** Plasma Exchange When Myeloma Presents as Acute Renal Failure. *Annals of Internal Medicine*; 143:777-784.
- Worel N, Greinix H, Ackermann J et al. (2001):** Deletion of chromosome 13q14 detected by fluorescence in situ hybridization has prognostic impact on survival after high-dose therapy in patients with multiple myeloma. *Ann Hematol* ; 80: 345–348.
- Yaccoby S, Ling W, Zhan F et al. (2007):** Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. *Blood*; 109(5), 2106–2111.
- Yaccoby S, Pearse RN, Johnson CL, Barlogie B, Choi Y and Epstein J. (2002):** Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. *Br. J. Haematol*; 116(2), 278–290.
- Ying WZ and Sanders PW. (2001):** Mapping the binding domain of immunoglobulin light chains for Tamm-Horsfall protein. *Am J Pathol*; 158: 1859–1866.
- Zangari M et al (2003):** The blood coagulation mechanism in multiple myeloma. *Semin Thromb Hemost*; 29(3): 275–282.
- Zangari M, Barlogie B, Anaissie E et al. (2004):** Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. *Br J Haematol*; 126: 715–721.
- Zangari M, Siegel E, Barlogie B, et al. (2002):** Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. *Blood*; 100:1168-1171.
- Zervas K, Verrou E, Teleioudis Z et al. (2006):** Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. *Br. J. Haematol*; 134(6), 620–623.
- Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, Anaissie E, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Walke R, Zangari M, Crowley J, Barlogie B, Shaughnessy JD Jr (2006):** The molecular classification of multiple myeloma. *Blood*; 108: 2020–2028.